• Home
• Partneringtools
• Reports

• In-licensing
• Out-licensing
• Companies

• Articles
• Events
• Outsourcing

• Consulting
• Jobs
• Forums

• About us
• Products
• Newsletter

Pharmalicensing Ltd
is a division of

— DALLAS and REYKJAVIK, Iceland, April 3

DALLAS and REYKJAVIK, Iceland, April 3 /PRNewswire/ -- U.S. Preventive Medicine(R), http://www.USPreventiveMedicine.com) the leader in prevention, and deCODE Genetics, the global leader in gene discovery, today announced they have signed a letter of intent to add genetic testing to expand both companies' personalized medicine services in the U.S. and internationally.

"The signing of the letter of intent with deCODE is significant because we will be the first entity in the U.S. and internationally to offer a full continuum of geographically dispersed, comprehensive solutions for personalized medicine including preventive care, wellness and disease management," said Christopher Fey, Chairman and CEO of U.S. Preventive Medicine. "We are very excited because our consumer, employer and physician customers will now be able to take advantage of a wide range of innovative personalized medicine services, including an opt-in genetic testing program for clients of our Centers for Preventive Medicine and members of The Prevention Plan. Our goal is to make the most advanced prevention strategies -- including more precise risk stratification -- available to informed consumers who want to use the best medicine has to offer to enjoy more good years."

Fey said U.S. Preventive Medicine's expansion into personalized medicine is the next step in the company's plan to provide practical solutions at every point in the healthcare continuum both nationally and internationally.

"The relationship with U.S. Preventive Medicine will offer us another platform to provide our genetic testing and personal genetics services through an innovative business model encompassing Centers for Preventive Medicine, as well as its new Prevention Plan health benefits," says Kari Stefansson, M.D., CEO of deCODE. "This partnership gives deCODE access to an even wider distribution channel of consumers, employers and providers to share knowledge, experiences, new technologies and services, while providing the best possible preventive health programs."

According to U.S. Preventive Medicine National Policy Advisor and former Secretary of the U.S. Department of Health & Human Services, Gov. Tommy Thompson, "The addition of deCODE's DNA profiling services as a option for the individuals the company assists is a natural evolution in the direction of the demand for personalized medicine. This is a very important step for U.S. Preventive Medicine in their role as the leader of this crucial area of health care."

About U.S. Preventive Medicine:

U.S. Preventive Medicine(R), a privately owned company, is building the first personalized medicine business in the United States and internationally focused on prevention. They offer employers, government agencies and consumers proprietary products that include The Prevention Plan(TM), a groundbreaking personalized wellness program delivered online to individuals; The Prevention Plan CM(TM), field-based chronic disease management programs customized for employers and government agencies to reduce healthcare costs; and The Centers for Preventive Medicine(R), which offer high-tech diagnostic screenings delivered to consumers in partnership with hospitals, health systems and other providers. For more information, please visit http://www.USPreventiveMedicine.com.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in personal genome analysis, DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics. Visit us on the web at http://www.decode.com; on our diagnostics website at http://www.decodediagnostics.com; and, for our pioneering personal genome analysis service, at http://www.decodeme.com.

Web site: http://www.USPreventiveMedicine.com http://www.decode.com http://www.decodediagnostics.com http://www.decodeme.com

• deCODE genetics

Industry news: Pharmalicensing provides comprehensive industry coverage.

Products:	Partnering Consulting	Partnering Search	Company Profiling	Comparision	Partneringtools	Reports
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Outsourcing
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search	Add your event
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic	Post your article
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Company releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us